The EPO published patent application EP3607053A1 for Cytoarm Co. Ltd. covering antigen-specific T cells and uses thereof for cancer treatment. The application includes IPC classifications C07K 16/28, C07K 16/30, C07K 16/32, C07K 16/46, C07K 16/40, C12N 5/0783, A61K 39/395, A61P 35/00, and A61K 39/00. The patent is designated for protection across 31 European member states including DE, FR, GB, IT, ES, NL, and others.

This is a patent publication rather than a regulatory action and creates no compliance obligations or deadlines. Competitors developing CAR-T therapies or other T cell-based oncology products should review the patent claims to assess potential overlap with their development programs.